Pasireotid ATC:H01CB05

TENDER DESCRIPTION

Kaufmännische Krankenkasse - KKH (hereinafter referred to as KKH) pursues the objective of concluding discount agreements pursuant to Section 130a(8) of SGB V with all suitable pharmaceutical companies regarding the active ingredient (ATC) stated under BT-21-Lot and, if applicable, restrictively to certain dosage forms within the scope of a so-called “Open-House procedure”. Under the condition of uniform contractual terms and a uniform access procedure, the conclusion of and accession to a discount agreement pursuant to Section 130a(8) of SGB V for the above-mentioned active ingredient is offered to all suitable and interested pharmaceutical companies or associations of pharmaceutical companies. Interested pharmaceutical companies may request the participation documents as well as the contract at the contact address specified. A prerequisite for concluding a contract is that the interested pharmaceutical company submits the requested participation documents in full and duly completed and signed. With each pharmaceutical company that meets the participation requirements, a contract is concluded. Exclusivity is not provided. Accession and/or conclusion of the contract may be made…

TENDER BRIEF

TENDER DOCUMENTS